BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.73 USD | +0.93% |
|
-3.07% | +25.72% |
| Sales 2024 * | 27.96M 2.33B | Sales 2025 * | 27.8M 2.32B | Capitalization | 970M 80.87B |
|---|---|---|---|---|---|
| Net income 2024 * | -228M -19.01B | Net income 2025 * | -265M -22.1B | EV / Sales 2024 * | 23.6 x |
| Net cash position 2024 * | 311M 25.94B | Net cash position 2025 * | 229M 19.05B | EV / Sales 2025 * | 26.7 x |
| P/E ratio 2024 * |
-4.29
x | P/E ratio 2025 * |
-4.07
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bicycle Therapeutics plc
More recommendations
More press releases
| 1 day | +0.93% | ||
| 1 week | -3.07% | ||
| Current month | -8.71% | ||
| 1 month | -7.34% | ||
| 3 months | +27.91% | ||
| 6 months | +49.05% | ||
| Current year | +25.72% |
1 week
22.00
23.65
1 month
21.6125.09
Current year
16.1327.24
1 year
12.5428.91
3 years
12.0862.08
5 years
6.2462.08
10 years
6.2462.08
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Lee
CEO | Chief Executive Officer | 55 | 01/15/01 |
Alethia Young
DFI | Director of Finance/CFO | 45 | 17/23/17 |
Alistair Milnes
COO | Chief Operating Officer | 50 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pierre Legault
CHM | Chairman | 63 | 18/19/18 |
| Director/Board Member | 61 | 17/21/17 | |
Richard Kender
BRD | Director/Board Member | 68 | 24/19/24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 22.73 | +0.93% | 143,698 |
| 25/24/25 | 22.52 | -0.66% | 118,003 |
| 24/24/24 | 22.67 | -0.04% | 518,131 |
| 23/24/23 | 22.68 | +0.49% | 163,474 |
| 22/24/22 | 22.57 | -3.75% | 395,115 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Calendar
02/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
22.73
USD
Average target price
43.99
USD
Spread / Average Target
+93.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.72% | 970M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BCYC Stock
